From made-to-order genetic therapies to model organisms engineered to be ‘patient avatars’, the technology exists right now to save patients with rare diseases.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
Communications Biology Open Access 23 April 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kim, J. et al. N. Engl. J. Med. 381, 1644–1652 (2019).
Crooke, S. T. et al. Nat. Rev. Drug Discov. 20, 427–453 (2021).
Woodcock, J. & Marks, P. N. Engl. J. Med. 381, 1678–1680 (2019).
Brudvig, J. J. & Weimer, J. M. J. Clin. Invest. https://doi.org/10.1172/JCI157820 (2022).
Korobeynikov, V. A., Lyashchenko, A. K., Blanco-Redondo, B., Jafar-Nejad, P. & Shneider, N. A. Nat. Med. 28, 104–116 (2022).
Aartsma-Rus, A. et al. Nucleic Acid Ther. https://doi.org/10.1089/nat.2022.0060 (2022).
Schor, N. F., Tamiz, A. P., Koroshetz, W. J., NINDS Ultra-Rare Gene-based Therapy (URGenT) Working Group & Broome, A.-M. Nat. Biotechnol. 39, 1497–1499 (2021).
Urnov, F. New York Times https://www.nytimes.com/2022/12/09/opinion/crispr-gene-editing-cures.html (9 December 2022).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Seydel, C. Personalized medicine is having its day. Nat Biotechnol 41, 441–446 (2023). https://doi.org/10.1038/s41587-023-01724-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-023-01724-9
This article is cited by
-
Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs
Communications Biology (2024)
-
Defining rare conditions in the era of personalized medicine
Nature Reviews Drug Discovery (2023)